Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 11/20 | 0.70 |
| ▸ | F2 | P00734 | 7/20 | 0.70 |
| ▸ | F12 | P00748 | 10/20 | 0.57 |
| ▸ | F10 | P00742 | 4/20 | 0.57 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.57 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.57 |
| ▸ | F7 | P08709 | 4/20 | 0.57 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.57 |
| ▸ | F9 | P00740 | 1/20 | 0.57 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.49 |
| ▸ | KLK1 | P06870 | 1/20 | 0.49 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7145838 | 1.00 | F11 (0.70) | F11F2F12F10PRSS1 | |
| SCHEMBL7165704 | 0.91 | F11 (0.72) | F11F2F12F10PRSS1 | |
| SCHEMBL6439064 | 0.89 | F2 (0.64) | F11F2F12F10PRSS1 | |
| SCHEMBL7957228 | 0.89 | F2 (0.64) | F11F2F12F10PRSS1 | |
| SCHEMBL7147704 | 0.89 | F11 (0.69) | F11F2F12F10PRSS1 | |
| SCHEMBL7708367 | 0.89 | F2 (0.64) | F11F2F12F10PRSS1 | |
| SCHEMBL7147026 | 0.88 | F11 (0.59) | F11F2F12F10PRSS1 | |
| Hydrochloric Acid SCHEMBL6438384 | 0.88 | F2 (0.61) | F11F2F12F10PRSS1 | |
| SCHEMBL6435616 | 0.87 | F2 (0.63) | F11F2F12F10PRSS1 | |
| SCHEMBL6437882 | 0.86 | F2 (0.64) | F11F2F12F10PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642253-B2 | Thrombin inhibitors comprising an aminoisoquinoline group | AKZO NOBEL N. V. (NL) | 2003-11-04 | — | — | US | disclosed |
| US-20030166579-A1 | THROMBIN INHIBITORS COMPRISING AN AMINOISOQUINOLINE GROUP | N.V. ORGANON (NL) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166579-A1 | THROMBIN INHIBITORS COMPRISING AN AMINOISOQUINOLINE GROUP | F2, TFPI, SERPINC1 | F11 15/4885F2 1/4885F12 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.